Natixis Nektar Therapeutics Transaction History

Natixis

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$3.17 - $6.17 $149,585 - $291,149	-47,188 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$4.16 - $13.72 $22,089 - $72,853	5,310 Added 12.68%	47,188 $254,000
Q2 2019 Aug 13, 2019	BUY	$31.0 - $36.3 $67,487 - $79,025	2,177 Added 5.48%	41,878 $1.49 Million
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $354,896 - $520,881	-11,238 Reduced 22.06%	39,701 $1.3 Million
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $690,882 - $1.29 Million	22,704 Added 80.41%	50,939 $1.67 Million
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $1.31 Million - $1.93 Million	28,235 New	28,235 $1.72 Million
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $922,992 - $1.74 Million	-16,080 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $99,078 - $260,392	4,304 Added 36.55%	16,080 $960,000
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $209,495 - $282,624	11,776	11,776 $283,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $171M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.